Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Podolife is the specialized podiatry division of Epitech Group, an Italian pharmaceutical company focused on the development of pharmacological solutions for foot and nail pathologies. The company utilizes the proprietary ALIA (Autacoid Local Injury Antagonism) technology, which leverages endogenous lipids like Palmitoylethanolamide (PEA) and its analogues to modulate mast cell hyperactivity and neuroinflammation. Podolife's product portfolio includes advanced topical treatments for complex conditions such as diabetic foot syndrome, as well as common podiatric issues like hyperkeratosis and nail dystrophies. By integrating dermatology, neurology, and vascular medicine, Podolife provides a comprehensive approach to the treatment of the foot as a complex organ system.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Podolife.